SCHEMBL5596997

SCHEMBL5596997

COc1ccc(C(F)(F)F)cc1N(C(N)=O)c1ccc(C)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.43
HCRTR1 O43613 1/20 0.42
HCRTR2 O43614 1/20 0.42
KDM4E B2RXH2 3/20 0.40
MEN1 O00255 3/20 0.40
ALDH1A1 P00352 3/20 0.40
KMT2A Q03164 3/20 0.40
HPGD P15428 2/20 0.40
CYP1A2 P05177 2/20 0.39
CYP2C19 P33261 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
GAA P10253 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
ERAP1 Q9NZ08 2/20 0.37
RAB9A P51151 1/20 0.37
CYP1A1 P04798 1/20 0.36
CYP1B1 Q16678 1/20 0.36
LMNA P02545 1/20 0.36
DHFR P00374 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13388895 0.89 MAPT (0.43) MAPTHCRTR1HCRTR2KDM4EMEN1
SCHEMBL6959867 0.88 MAPT (0.37) MAPTHCRTR1HCRTR2GAAPTGDR2
SCHEMBL13388545 0.85 MAPT (0.43) MAPTHCRTR1HCRTR2KDM4EALDH1A1
SCHEMBL6364181 0.82 POLQ (0.41) MAPTHCRTR1HCRTR2PTGDR2ERAP1
SCHEMBL13388542 0.80 MAPT (0.40) MAPTHCRTR1HCRTR2KDM4EMEN1
SCHEMBL13388156 0.79 EPAS1 (0.39) MAPTHCRTR1HCRTR2HPGDCYP2C19
SCHEMBL1513789 0.78 ERAP1 (0.47) MAPTERAP1RAB9ALMNAMRGPRX4
SCHEMBL7964989 0.76 RAF1 (0.53) MEN1KMT2A
SCHEMBL6249040 0.76 RAF1 (0.43) MAPTKDM4ERAB9A
SCHEMBL6668753 0.75 MEN1 (0.46) MAPTKDM4EMEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER HEALTHERCARE LLC (US) 2012-10-25 US claimed
JP-3887769-B2 2007-02-28 JP claimed
EP-1042305-A4 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER AG (US) 2003-05-14 EP claimed
JP-2001526276-A 2001-12-18 JP claimed
EP-1042305-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS Bayer Corporation (US) 2000-10-11 EP claimed
WO-1999032463-A1 INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS BAYER CORPORATION (US) 1999-07-01 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270878-A1 INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS MAP2K2, MAPK1, MAP2K1 MAPT 618/4885HCRTR1 4428/4885HCRTR2 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.